Navigation Links
First evidence from humans on how alcohol may boost risk of cancer
Date:8/22/2012

PHILADELPHIA, Aug. 22, 2012 Almost 30 years after discovery of a link between alcohol consumption and certain forms of cancer, scientists are reporting the first evidence from research on people explaining how the popular beverage may be carcinogenic. The results, which have special implications for hundreds of millions of people of Asian descent, were reported here today at the 244th National Meeting & Exposition of the American Chemical Society.

Silvia Balbo, Ph.D., who led the study, explained that the human body breaks down, or metabolizes, the alcohol in beer, wine and hard liquor. One of the substances formed in that breakdown is acetaldehyde, a substance with a chemical backbone that resembles formaldehyde. Formaldehyde is a known human carcinogen. Scientists also have known from laboratory experiments that acetaldehyde can cause DNA damage, trigger chromosomal abnormalities in cell cultures and act as an animal carcinogen.

"We now have the first evidence from living human volunteers that acetaldehyde formed after alcohol consumption damages DNA dramatically," Balbo said. She is a research associate in the laboratory of Stephen Hecht, Ph.D., a noted authority on cancer prevention at the University of Minnesota. "Acetaldehyde attaches to DNA in humans ― to the genetic material that makes up genes - in a way that results in the formation of a 'DNA adduct.' It's acetaldehyde that latches onto DNA and interferes with DNA activity in a way linked to an increased risk of cancer."

Balbo pointed out that people have a highly effective natural repair mechanism for correcting the damage from DNA adducts. Most people thus are unlikely to develop cancer from social drinking, although alcohol is associated with a risk of other health problems and accidents. In addition, most people have an enzyme called alcohol dehydrogenase, which quickly converts acetaldehyde to acetate, a relatively harmless substance.

However, about 30 percent of people of Asian descent ― almost 1.6 billion people ― have a variant of the alcohol dehydrogenase gene and are unable to metabolize alcohol to acetate. That genetic variant results in an elevated risk of esophageal cancer from alcohol drinking. Native Americans and native Alaskans have a deficiency in the production of that same enzyme.

To test the hypothesis that acetaldehyde causes DNA adducts to form in humans, Balbo and colleagues gave 10 volunteers increasing doses of vodka (comparable to one, two and three drinks) once a week for three weeks. They found that levels of a key DNA adduct increased up to 100-fold in the subjects' oral cells within hours after each dose, then declined about 24 hours later. Adduct levels in blood cells also rose.

"These findings tell us that alcohol, a lifestyle carcinogen, is metabolized into acetaldehyde in the mouth, and acetaldehyde is forming DNA adducts, which are known major players in carcinogenesis," said Balbo.


'/>"/>

Contact: Michael Bernstein
m_bernstein@acs.org
215-418-2056 (Philadelphia Press Center, Aug. 17-23)
202-872-6042

Michael Woods
m_woods@acs.org
215-418-2056 (Philadelphia Press Center, Aug. 17-23)
202-872-6293
American Chemical Society


Source:Eurekalert

Related medicine news :

1. First identification of a strong oral carcinogen in smokeless tobacco
2. IHME professor named first health measurement winner of prestigious innovation award
3. FDA Gives Nod to First Drug for Diabetic Eye Disease
4. Mayo Clinic completes first genome-wide analysis of peripheral T-cell lymphomas
5. Women and Children First? Not So, Says Study
6. WPI to host international workshop focused on technology solutions for first responders
7. First Huntingtons disease center established in Washington, D.C., area
8. Study Gives First Evidence That Adult Human Lungs Can Regrow
9. Hookah smoking increasingly common among first-year college women
10. Sohn Conference and Damon Runyon Cancer Research Foundations name first pediatric research fellows
11. Scientists first to see trafficking of immune cells in beating heart
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... March 23, 2017 , ... The StayWell Company ... NCQA. The accreditation covers StayWell’s asthma, coronary artery disease, congestive heart failure, chronic ... organizations that have excellent programs for the delivery and improvement of disease management ...
(Date:3/23/2017)... , ... March 23, 2017 , ... ... families and businesses of the greater Fort Collins area, has unveiled a collaboration ... ongoing community involvement program. Donations to this worthy cause may now be made ...
(Date:3/23/2017)... ... , ... ?This conference will prominently feature 150+ Hospital and Health System Executive Speakers including: , ... , 43rd President of the United States of America: George W. Bush , ... Out of the Ring: Sugar Ray Leonard , JD, Chairperson, McGuireWoods LLP: Amber ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... improve all aspects of people’s health and nutrition, announced its product Leyzene is ... , Natural Subsistence develops nutritional supplements that help people improve all aspects of ...
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... The American ... 2017 marks the 40th Anniversary of ABQAURP’s dedication to Health Care Quality and Management ... who have contributed not only to the association, but also to the Health Care ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... On Wednesday, March 22, ... at 5,821.64, up 0.48%; the Dow Jones Industrial ... and the S&P 500 closed at 2,348.45, slightly ... out of nine sectors ended the day in ... on the following Medical Instruments & Supplies equities: ...
(Date:3/23/2017)... 2017 Piramal Pharma ... gibt die Ernennung von Stuart E. Needleman ... globalen Pharmazeutikkunden eine einmalige integrierte End-to-End-Serviceplattform an ... für das erfolgreiche Wachstum und die Umsetzung ... Herr Needleman dafür verantwortlich sein, alle globalen ...
(Date:3/23/2017)... 23, 2017 Merrimack Pharmaceuticals, Inc. (NASDAQ: ... patient in a Phase 1 study of MM-310 in ... encapsulates a novel taxane and targets the EphA2 receptor, ... of many major tumor types, including prostate, ovarian, bladder, ... of this study is an important step in evaluating ...
Breaking Medicine Technology: